Histone deacetylase (HDAC) inhibitor chidamide was recently approved for treating relapsed/refractory peripheral T-cell lymphoma (PTCL) patients. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.